DeepMed Research

Sandoz Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Inflammation

Interventions: Drug: Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
Drug: Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
Drug: Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)

First Posted Date: 2009-06-04

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 18

Registration Number: NCT00914160

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

Phase 1

Completed

Conditions: Anxiety

Interventions: Drug: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)

First Posted Date: 2009-06-03

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 26

Registration Number: NCT00912145

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
Drug: Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)

First Posted Date: 2009-04-20

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 40

Registration Number: NCT00883883

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Type II Diabetes

Interventions: Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

First Posted Date: 2009-04-17

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 16

Registration Number: NCT00882882

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Lisinopril 40 mg Tablet under fed conditions.
Drug: Lisinopril 40 mg Tablet (Zestril) under fed conditions.
Drug: Lisinopril 40 mg Tablet under fasting conditions.

First Posted Date: 2009-04-17

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 24

Registration Number: NCT00883506

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bupropion HCl 100 mg Tablets (Invamed Inc.)
Drug: Wellbutrin 100 mg Tablets (Glaxo Wellcome)

First Posted Date: 2009-04-17

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 36

Registration Number: NCT00883155

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
Drug: Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)

First Posted Date: 2009-04-17

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 32

Registration Number: NCT00883064

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)

First Posted Date: 2009-04-16

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 28

Registration Number: NCT00882700

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Drug: Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)

First Posted Date: 2009-04-16

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 40

Registration Number: NCT00882570

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)

First Posted Date: 2009-04-16

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 28

Registration Number: NCT00882154

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy